Switch theme
Sign up to access all valuation multiples
TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).
2015
12
Last FY Revenue n/a
LTM EBITDA -$3.6M
$5.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
TME Pharma has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$3.6M.
In the most recent fiscal year, TME Pharma achieved revenue of n/a and an EBITDA of -$5.8M.
TME Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TME Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$3.6M | XXX | -$5.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$3.6M | XXX | -$5.9M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$4.2M | XXX | -$6.4M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, TME Pharma's stock price is EUR 0 (or $0).
TME Pharma has current market cap of EUR 8.0M (or $8.9M), and EV of EUR 4.7M (or $5.3M).
See TME Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.3M | $8.9M | XXX | XXX | XXX | XXX | $-0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, TME Pharma has market cap of $8.9M and EV of $5.3M.
TME Pharma's trades at n/a EV/Revenue multiple, and -0.9x EV/EBITDA.
Equity research analysts estimate TME Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TME Pharma has a P/E ratio of -2.1x.
See valuation multiples for TME Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.9M | XXX | $8.9M | XXX | XXX | XXX |
| EV (current) | $5.3M | XXX | $5.3M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -1.5x | XXX | -0.9x | XXX | XXX | XXX |
| EV/EBIT | -1.5x | XXX | -0.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.1x | XXX | -1.4x | XXX | XXX | XXX |
| EV/FCF | -1.5x | XXX | -1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTME Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.5M for the same period.
TME Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TME Pharma's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for TME Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 80% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TME Pharma acquired XXX companies to date.
Last acquisition by TME Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . TME Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was TME Pharma founded? | TME Pharma was founded in 2015. |
| Where is TME Pharma headquartered? | TME Pharma is headquartered in France. |
| How many employees does TME Pharma have? | As of today, TME Pharma has 12 employees. |
| Is TME Pharma publicy listed? | Yes, TME Pharma is a public company listed on PAR. |
| What is the stock symbol of TME Pharma? | TME Pharma trades under ALTME ticker. |
| When did TME Pharma go public? | TME Pharma went public in 2016. |
| Who are competitors of TME Pharma? | Similar companies to TME Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of TME Pharma? | TME Pharma's current market cap is $8.9M |
| Is TME Pharma profitable? | Yes, TME Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of TME Pharma? | TME Pharma's last 12 months EBITDA is -$3.6M. |
| What is the current EV/EBITDA multiple of TME Pharma? | Current EBITDA multiple of TME Pharma is -1.5x. |
| What is the current FCF of TME Pharma? | TME Pharma's last 12 months FCF is -$3.6M. |
| What is the current EV/FCF multiple of TME Pharma? | Current FCF multiple of TME Pharma is -1.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
